# Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

> **NCT02435680** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

## Interventions

- **DRUG:** MCS110
- **DRUG:** carboplatin
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT02435680
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-10
- **Primary completion:** 2020-01-04
- **Final completion:** 2020-03-23
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435680, "Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02435680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*